Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Эффективность и безопасность применения индапамида ретард у женщин с артериальной гипертензией и сахарным диабетом: результаты исследования АФИНА
Эффективность и безопасность применения индапамида ретард у женщин с артериальной гипертензией и сахарным диабетом: результаты исследования АФИНА
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Women with diabetes: quality of health care, 2004–2005. Доступно на http://ahrq.hhs.gov
2. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332 (7533): 73–8.
3. Hu G, DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 2003; 46 (5): 608–17.
4. Глезер М.Г., Сайгитов Р.Т. Эффективность лечения артериальной гипертонии индапамидом замедленного высвобождения у мужчин и женщин в зависимости от наличия сахарного диабета 2-го типа. Результаты программы БОЛЕРО. Проблемы женского здоровья 2008; 3 (4): 5–13.
5. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162–72.
6. Khan NA, Hemmelgarn B, Herman RJ et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2-therapy. Can J Cardiol 2009; 25 (5): 287–98.
7. Глезер М.Г., Сайгитов Р.Т. Артериальная гипертония у женщин в условиях поликлинической практики. Результаты эпидемиологического исследования АФИНА. Проблемы женского здоровья. 2009. 4 (1): 5–17.
8. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33 (Suppl. 1): 11–61.
9. Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43 (5): 963–9.
10. Smith NL, Barzilay JI, Kronmal R et al. New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study. Diabetes Care 2006; 29 (9): 2012–7.
11. Barnett KN, Ogston SA, McMurdo ME et al. A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland. Diabet Med 2010; 27 (10): 1124–9.
12. Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166 (20): 2191–201.
13. Whelton PK, Barzilay J, Cushman WC et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165 (12): 1401–9.
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317 (7160): 703–13.
15. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165 (12): 1410–9.
16. Newman DJ, Mattock MB, Dawnay AB et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9 (30): 163.
17. Mancia G, De Backer G, Dominiczak A. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105–87.
18. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560–72.
2. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332 (7533): 73–8.
3. Hu G, DECODE Study Group. Gender difference in all-cause and cardiovascular mortality related to hyperglycaemia and newly-diagnosed diabetes. Diabetologia 2003; 46 (5): 608–17.
4. Глезер М.Г., Сайгитов Р.Т. Эффективность лечения артериальной гипертонии индапамидом замедленного высвобождения у мужчин и женщин в зависимости от наличия сахарного диабета 2-го типа. Результаты программы БОЛЕРО. Проблемы женского здоровья 2008; 3 (4): 5–13.
5. Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162–72.
6. Khan NA, Hemmelgarn B, Herman RJ et al. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2-therapy. Can J Cardiol 2009; 25 (5): 287–98.
7. Глезер М.Г., Сайгитов Р.Т. Артериальная гипертония у женщин в условиях поликлинической практики. Результаты эпидемиологического исследования АФИНА. Проблемы женского здоровья. 2009. 4 (1): 5–17.
8. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care 2010; 33 (Suppl. 1): 11–61.
9. Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43 (5): 963–9.
10. Smith NL, Barzilay JI, Kronmal R et al. New-onset diabetes and risk of all-cause and cardiovascular mortality: the Cardiovascular Health Study. Diabetes Care 2006; 29 (9): 2012–7.
11. Barnett KN, Ogston SA, McMurdo ME et al. A 12-year follow-up study of all-cause and cardiovascular mortality among 10,532 people newly diagnosed with Type 2 diabetes in Tayside, Scotland. Diabet Med 2010; 27 (10): 1124–9.
12. Barzilay JI, Davis BR, Cutler JA et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006; 166 (20): 2191–201.
13. Whelton PK, Barzilay J, Cushman WC et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165 (12): 1401–9.
14. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317 (7160): 703–13.
15. Turnbull F, Neal B, Algert C et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165 (12): 1410–9.
16. Newman DJ, Mattock MB, Dawnay AB et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol Assess 2005; 9 (30): 163.
17. Mancia G, De Backer G, Dominiczak A. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25 (6): 1105–87.
18. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560–72.
Авторы
М.Г.Глезер, Р.Т.Сайгитов от имени участников исследования АФИНА
ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ;
Городская клиническая больница №59, Москва
ГОУ ВПО Первый МГМУ им. И.М.Сеченова Минздравсоцразвития РФ;
Городская клиническая больница №59, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.